Full Press Release Details
InMed's Neurodegenerative Disease Study
Presented at Canadian Neuroscience Meeting
Vancouver, BC - June 1, 2023 - InMed
Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical
research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that results
from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May
The InMed sponsored research, entitled "Cannabinoids
modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells", demonstrated the ability of a specific rare
cannabinoid ("pCBx") in InMed's 900 Series library of potential candidates that reduces amyloid toxicity and tau protein
expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential
treatment of neurodegenerative diseases such as Alzheimer's. The research was conducted in the laboratory of Dr. Ujendra Kumar and
Dr. Rishi Somvanshi of the faculty of Pharmaceutical Sciences at the University of British Columbia. Studies have shown that cannabinoids,
via their endocannabinoid receptors (CB1R and CB2R) that naturally occur in the human body and brain, reduce amyloid-beta ("A ")
toxicity, decrease p-tau protein expression and provide neurite outgrowth, thus improving neuronal viability and function.
The results presented demonstrate the anti-apoptotic
effects of pCBx and its role in neuritogenesis in the cells of neuronal origin and support the role of pCBx as a potential therapeutic
intervention in neurodegenerative diseases.
To learn more on the research, a copy of the poster
INM-900 Series Program: a unique
approach to treating neurodegenerative diseases
InMed has conducted research demonstrating how
a specific rare cannabinoid and its analogs inhibit or slow the progression of neurodegenerative disease. These rare cannabinoids demonstrated
neuroprotective effects in a population of affected neurons and promoted neurite outgrowth, signifying the potential to enhance neuronal
function. Two cannabinoid analogs showing the most promising effects in neuroprotection and enhanced neuronal function have advanced to
in vivo studies. This research is being funded in part by a grant awarded to Dr. Ujendra Kumar from the Natural Sciences and Engineering
Research Council of Canada (NSERC).
InMed has filed an international patent
application demonstrating neuroprotection and enhanced neuronal function using rare cannabinoids and analogs for the potential treatment
of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and others. The
patent specifies such compounds that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in
a population of affected neurons.
InMed Pharmaceuticals is a global leader
in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches
to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Forward-looking information in this news release includes statements about: the increasing demand for rare cannabinoids; InMed's
participation in future conferences; demonstrating the ability of a specific rare cannabinoid to be important targets in the potential
treatment of neurodegenerative diseases such as Alzheimer's; demonstrating the anti-apoptotic effects of pCBx and its role in neuritogenesis
in the cells of neuronal origin and support the role of pCBx as a potential therapeutic intervention in neurodegenerative diseases; demonstrating
how a specific rare cannabinoid and its analogs inhibit or slow the progression of neurodegenerative disease; being a global leader in
the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs; having significant know-how in developing proprietary manufacturing approaches
to produce cannabinoids for various market sectors.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties
facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities
and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.